[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100585334":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":32,"locations":18,"responsibleParty":41,"collaborators":44,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":49,"sex":54,"minAge":55,"maxAge":18,"enrollmentInfo":56,"targetDuration":18,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":68,"whyStopped":18,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":18},{"fullName":5,"class":6},"Fundacion Clinic per a la Recerca Biomédica","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","Effluent dose schedule of 10-20 ml\u002Fkg\u002Fh after 48 hours of starting dose of 25-35 ml\u002Fkg\u002Fh, until completing 96 hours",[13],"Procedure: continuous renal replacement therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Effluent dosage schedule of 25-35 ml\u002Fkg\u002Fh fixed for 96 hours",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"PROCEDURE","continuous renal replacement therapy","Intervention Arm: Effluent dose schedule of 10-20 ml\u002Fkg\u002Fh after 48 hours of starting dose of 25-35 ml\u002Fkg\u002Fh, until completing 96 hours\n\nControl Arm Effluent dosage schedule of 25-35 ml\u002Fkg\u002Fh fixed for 96 hours",[9],[26],"continuous renal replacement dose",[28],{"name":29,"affiliation":30,"role":31},"Gaston J Piñeiro, MD, PhD","Hospital Clínic of Barcelona","PRINCIPAL_INVESTIGATOR",[33,38],{"name":29,"role":34,"phone":35,"phoneExt":36,"email":37},"CONTACT","+34932275400","5400 \u002F 3474","GJPINEIR@CLINIC.CAT",{"name":39,"role":34,"phone":35,"phoneExt":18,"email":40},"Enric Reverter, MD, PhD","ereverte@clinic.cat",{"type":31,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Fritz Diekmann","Research Coordinator of the Institute of Nephrology and Urology (ICNU) at Hospital Clínic de Barcelona",[45],{"name":46,"class":6},"Hospital Clinic of Barcelona","100585334","continuous-renal-replacement-therapy-doses-in-critically-ill-patients-with-acute-kidney-injury-100585334",false,"NCT06901011","Continuous Renal Replacement Therapy Doses in Critically Ill Patients With Acute Kidney Injury","CRRIT1","Inclusion Criteria:\n\n* Patients 18 years of age or older\n* Acute renal failure (AKIN 3) requiring Continuous Renal Replacement Therapy\n* Requirement of vasoactive drugs (norepinephrine \\> 0.1 mcg\u002Fkg\u002Fmin)\n* Written informed consent (patient or family)\n\nExclusion Criteria:\n\n* Lack of informed consent.\n* Possibility of using plasma exchange or MARS therapy at the at the time of inclusion.\n* Baseline renal function with an estimated glomerular filtration rate (CKD-EPI) less than 30 ml\u002Fmin.","ALL","18 Years",{"count":57,"type":58},100,"ESTIMATED","INTERVENTIONAL",[61],"NA","Acute kidney injury in critically ill patients admitted to the ICU is a common complication associated with high mortality or long-term chronic kidney damage. Some of these patients require continuous renal replacement therapy (low-intensity hemodialysis for 24 hours) until renal function recovery is achieved.\n\nContinuous Renal Replacement Therapy (CRRT) is a crucial treatment for ICU patients with acute renal failure. It offers continuous toxin removal and prevents fluid accumulation in the patient's body. The therapy not only eliminates toxins but also physiological substances, including micronutrients and essential elements for cellular metabolism and organ function.\n\nCurrently, there is limited information available to adjust the renal therapy dose and avoid or balance the loss of these substances without causing toxin accumulation. Some studies suggest that high doses of therapy do not provide benefits and increase complications.\n\nThe objective of this study is to evaluate two doses of continuous renal therapy in terms of internal environment control (sodium, potassium, and acids and bases), micronutrient loss, and toxin elimination. After 48 hours of therapy, patients will be assigned to continue with a dose equal to the initial dose or a decrease in the initial dose. These two options are part of the current standard practice in our center.\n\nPatients participating in the study will be randomly assigned one of the continuous renal therapy doses. The study is open, so treating physicians will always know the therapy the patient is receiving and can freely adjust it if deemed necessary.\n\nThe intervention duration is 96 hours, after which the dose will be at the discretion of the treating medical team. A follow-up will be conducted through medical records or phone calls approximately 90 days after starting therapy.\n\nThe risks for the patient are minimal, as toxin elimination monitoring will be even more intensive than usual. The study plans to include approximately 100 patients.",[64,65],"Renal Replacement Therapy for Acute Kidney Injury in ICU","Continuous Renal Replacement Therapy (CRRT)",[65,64,67],"dialytrauma","NOT_YET_RECRUITING","2025-07-14",{"date":71,"type":72},"2025-07-17","ACTUAL",{"date":74,"type":58},"2025-08-01",{"date":76,"type":58},"2027-08",{"name":5,"class":6}]